OncoZenge

6.47 SEK

-3.58 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-3.58 %

+27.11 %

+2.54 %

+17.42 %

+72.53 %

+42.35 %

+24.42 %

-

-47.13 %

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Market cap

81.83M SEK

Turnover

322.59K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18/2

2026

Annual report '25

20/5

2026

Interim report Q1'26

27/5

2026

General meeting '26

All

Press releases

3rd party

ShowingAll content types

Press release14 hours ago

Impala Nordic: OncoZenge - Execution enhanced through expanded Molteni partnership

Press releaseyesterday

OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge™ for Europe

Press release11/17/2025, 9:00 AM

OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge™

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/10/2025, 10:33 AM

Analyst Group: Analyst Group intervjuar OncoZenge VD Stian Kildal

Press release10/31/2025, 9:41 AM

BioStock: OncoZenge rustar för fas III efter starkt kvartal

Press release10/31/2025, 9:41 AM

BioStock: OncoZenge gearing up for phase III after a strong quarter

Press release10/30/2025, 1:52 PM

Redeye: OncoZenge (Q3 review) - Gearing up for a transformative 2026

Regulatory press release10/30/2025, 7:00 AM

OncoZenge AB Interim Report January 1 – September 30, 2025

Press release10/13/2025, 8:20 AM

BioStock: UCLA-studie ger OncoZenge patientperspektiv inför fas III-start

Press release10/13/2025, 8:20 AM

BioStock: UCLA study provides OncoZenge with patient insights ahead of phase III

Press release10/9/2025, 6:45 AM

OncoZenge AB: First Patient Enrolled in UCLA Patient Engagement Study

Regulatory press release10/8/2025, 5:50 PM

OncoZenge AB Nomination Committee Appointed

Press release9/22/2025, 1:20 PM

OncoZenge AB - Capital Markets Day 2025 On-Demand Video Now Available

Press release9/17/2025, 6:50 AM

OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™

Press release9/12/2025, 7:40 AM

Impala Nordic: OncoZenge - Execution advancing for Phase III study with LINK Medical as CRO

Press release9/10/2025, 3:10 PM

OncoZenge AB appoints LINK Medical as CRO for BupiZenge™ Phase III execution

Press release8/27/2025, 2:00 PM

OncoZenge AB: Invitation to OncoZenge's Capital Markets Day on 18 September 2025

Press release8/21/2025, 12:30 PM

Impala Nordic: OncoZenge - Rapportintervju: Tar nästa steg med tillverkning och site selection för fas 3-studien

Press release8/21/2025, 12:00 PM

Impala Nordic: OncoZenge - Rapportkommentar: Förberedelser inför fas 3-studie i fokus

Press release8/21/2025, 9:46 AM

Redeye: OncoZenge Q2 - Financed for fully European phase III study

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.